S&P/ASX 200 Index (ASX: XJO) investors in their 40s still have 15–25 years until retirement. Investors in this demographic are generally at the peak of their income-earning potential. This should allow them to invest significant amounts of capital into the share market, with plenty of time to generate compounding returns.

ASX 200 investors in their 40s

As investors, we’re a motley crew. We all have motley goals, motley resources and motley risk appetite. Because of this, it is important to understand your own personal circumstances and invest accordingly. The below ASX shares will be fantastic options for most investors in their 40s, but not for all. 

With so much time left until retirement, growth shares are still a fantastic option for investors in their 40s.

3 best ASX 200 shares to buy now

Nanosonics Ltd (ASX: NAN)

Nanosonics employs a razor and blade business model that I am a huge fan of. The company sells its Trophon disinfection machines at near cost price but then sells high margin consumables to the installed base of users. This provides amazing economics for a business that can grow its installed base.

Nanosonics has said their Q4 and thus FY20 installed base growth may be impacted by direct access to hospitals. Prior to this, their global installed base grew 17% in the last 12 months and 8% in the last 6 months. 

Magellan Financial Group Ltd (ASX: MFG)

Magellan has been an incredible investment since it was founded in 2006 by Hamish Douglass and Chris Mackay. Over the last 15 years, the Magellan share price has provided total returns of nearly 35% per annum.

Magellan offers two market-leading strategies, global equities and global listed infrastructure. The business has multiple funds on offer on the ASX and earns revenue through management fees and the like.

The share price is currently down 21% from its 14 February highs.

Resmed Inc (ASX: RMD)

Resmed is one of the few businesses to have benefited from the coronavirus pandemic, but that doesn’t mean it isn’t a great buy for the long term. 

The medical device company has a large total addressable market, with a focus on sleep apnea. Sleep apnea is majorly under-diagnosed, meaning education is important. As more people become aware of the condition, Resmed could grab market share in a growing market thanks to its high-quality products.

Further to this, the company has more recently looked at data and analysis as growth drivers. The share price is currently 10% below its 20 February highs, presenting a nice long term entry point.

Foolish bottom line

It’s worth noting that I own two of these ASX 200 shares, despite being in my mid-20s. Why? Because they are high-quality businesses with a proven track record over the long term.

More reading

• ASX 200 down 0.1%: Big four banks drag ASX lower ahead of RBA meeting
• Is the Newcrest Mining share price a buy?
• Is the NAB share price cheap today?
• The big oil price recovery and bounce in ASX oil stocks are bringing out the bears
• 2 ASX 200 shares to watch on Tuesday

Lloyd Prout owns shares of Nanosonics Limited and Resmed Inc. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Nanosonics Limited. The Motley Fool Australia has recommended Nanosonics Limited and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Nanosonics Limited. The Motley Fool Australia has recommended Nanosonics Limited and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post ASX 200 investor in your 40s? 3 shares to buy now appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2ZYRqs7

In early afternoon trade the S&P/ASX 200 Index (ASX: XJO) has given back its morning gains and is dropping lower. At the time of writing the benchmark index is down 0.2% to 5,806.9 points.

Four shares that have not been able to follow the market higher today are listed below. Here’s why they are dropping lower:

The Evolution Mining Ltd (ASX: EVN) share price has fallen 2.5% to $6.14. A slight softening of the gold price is weighing on the gold miners today. In other news, this morning Evolution responded to media speculation and confirmed that it has been evaluating the possible divestment of its Cracow gold mine.

The Iress Ltd (ASX: IRE) share price has fallen 2% to $11.00. This morning the financial technology company’s shares returned from a trading halt after raising $150 million via an institutional placement. These funds were raised at $10.42 per new share, which represents a discount of 7%. The proceeds will be used to acquire Onevue Holdings Ltd (ASX: OVH).

The Pro Medicus Limited (ASX: PME) share price is down 3% to $28.48. The catalyst for this appears to be a broker note out of UBS this morning. It has downgraded the healthcare imaging software provider’s shares to a neutral rating with a $29.65 price target. While the broker likes Pro Medicus and was pleased with its latest contract win, it isn’t a fan of its current valuation.

The Vicinity Centres (ASX: VCX) share price has returned from its trading halt and dropped 3.5% to $1.54. This follows the completion of the shopping centre operator’s $1.2 billion institutional placement. Vicinity raised the funds at $1.48 per share, which represents a discount of 8% to its last close price. The proceeds will be used to strengthen its balance sheet during the tough trading conditions it is facing.

More reading

• ASX 200 down 0.1%: Big four banks drag ASX lower ahead of RBA meeting
• Why you might want to own ASX mining shares in 2020
• Forget cheap stocks. Why investors should watch ASX gold shares instead
• The latest ASX 200 stocks to be upgraded by top brokers
• ASX 200 up 0.6%: NAB charges higher, ACCC investigates Qantas acquisition

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended IRESS Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why Evolution, Iress, Pro Medicus, & Vicinity shares are dropping lower appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3gJIxbS

It has been a volatile day of trade for the S&P/ASX 200 Index (ASX: XJO) on Tuesday. At lunch the benchmark index has given back its late morning gains and is now down 0.1% to 5,812.6 points.

Here’s what has been happening on the market today:

Bank shares drop lower.

The big four banks are trading lower ahead of the Reserve Bank’s meeting this afternoon. At lunch all of the big four are in the red and acting as a drag on the index. The worst performer in the group has been the Westpac Banking Corp (ASX: WBC) share price with a 1% decline.

ANZ asset sale.

The Australia and New Zealand Banking GrpLtd (ASX: ANZ) share price is trading lower today after announcing an asset sale. ANZ has agreed to sell its New Zealand asset finance business, UDC Finance, to Japan’s Shinsei Bank for NZ$762 million. The sale will provide ~A$439 million (~10bps) of Level 2 Group CET1 capital at settlement. It will also release more than NZ$2 billion of funding provided by ANZ New Zealand.

Vicinity completes placement.

The Vicinity Centres (ASX: VCX) share price has dropped lower after returning from its trading halt. This follows the completion of its $1.2 billion institutional placement. These funds were raised at $1.48 per share, representing a discount of 8% to its last close price. Management advised that the equity raising will strengthen its balance sheet and provide the shopping centre operator with flexibility to respond to the uncertainty caused by COVID-19 and the evolving retail landscape.

Best and worst ASX 200 performers.

The best performer on the ASX 200 on Tuesday has been the Domain Holdings Australia Ltd (ASX: DHG) share price with an 8.5% gain. This may be down to better than expected Australian house price data. The worst performer has been the Vicinity share price with a 3.5% decline after its placement.

More reading

• ASX 200 investor in your 40s? 3 shares to buy now
• Why Evolution, Iress, Pro Medicus, & Vicinity shares are dropping lower
• Is the Newcrest Mining share price a buy?
• Is the NAB share price cheap today?
• ANZ share price climbs higher on asset sale

Motley Fool contributor James Mickleboro owns shares of Westpac Banking. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post ASX 200 down 0.1%: Big four banks drag ASX lower ahead of RBA meeting appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2MoomSw